Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #29 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Caplin Point Laboratories Limited (this stock) | 19,793 | 45.9 | 17.9% | 28.8% | — | 72 | 20 | 50 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 610 | 225 | 179 | ₹ |
| March 31, 2026 | 600 | 213 | 173 | ₹ |
| Dec. 31, 2025 | 543 | 204 | 166 | ₹ |
| Sept. 30, 2025 | 534 | 201 | 160 | ₹ |
| June 30, 2025 | 510 | 184 | 151 | ₹ |
| March 31, 2025 | 502 | 177 | 145 | ₹ |
| Dec. 31, 2024 | 493 | 177 | 140 | ₹ |
| Sept. 30, 2024 | 483 | 169 | 131 | ₹ |
| June 30, 2024 | 459 | 154 | 125 | ₹ |
| March 31, 2024 | 453 | 146 | 121 | ₹ |
| Dec. 31, 2023 | 436 | 145 | 120 | ₹ |
| Sept. 30, 2023 | 410 | 146 | 116 | ₹ |
| June 30, 2023 | 395 | 127 | 104 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,187 | 803 | 650 |
| March 31, 2025 | 1,937 | 677 | 541 |
| March 31, 2024 | 1,694 | 564 | 461 |
| March 31, 2023 | 1,467 | 451 | 377 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 523 | -582 | -46 | 248 | 275 |
| March 31, 2025 | 432 | -335 | -38 | 192 | 241 |
| March 31, 2024 | 311 | -313 | -38 | 146 | 165 |
| March 31, 2023 | 272 | -218 | -28 | 194 | 78 |
| March 31, 2022 | 337 | -271 | -41 | 91 | 246 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 4,045 | 3,631 | 3,571 | 1 | 0 | 2,586 | 386 | 94 | 547 | 429 |
| March 31, 2025 | 3,209 | 2,886 | 2,835 | 1 | 0 | 2,134 | 306 | 199 | 530 | 336 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
